Himalaya Nutravedics India IPO

About Himalaya Nutravedics India IPO

The Himalaya Nutravedics India IPO, an SME IPO, opens on 22 September 2026 and closes on 24 September 2026. The allotment of shares will take place on 25 September 2026. The credit of shares to the demat account and initiation of refunds will take place on 28 September 2026. The listing of shares will take place on 29 September 2026.

The offer consists of a fresh issue of 24,99,600 equity shares aggregating up to ₹26 crore, with no offer for sale component.

Himalaya Nutravedics India IPO’s price band is set at ₹100 to ₹106 per share. The lot size for an application is 1,200 shares. The minimum amount of investment required by a retail investor is ₹2,54,400 (2,400 shares) based on the upper price band. The minimum lot size investment for S-HNI is ₹3,81,600 (3,600 shares).

Himalaya Nutravedics India is engaged in the manufacturing, marketing and distribution of Ayurvedic and Nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and Nutraceutical companies. It manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations based on compositions and processes described in traditional Ayurvedic texts, proprietary Ayurvedic formulations and Nutraceutical products across multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils.

Objectives of Himalaya Nutravedics India IPO

• Funding working capital requirements.
  
• Investment in branding, digital marketing and sales expansion.
  
• General corporate purposes.
  

Industry Outlook

The Ayurvedic formulations and nutraceuticals industry is a specialised segment within India’s pharmaceutical and wellness ecosystem, covering the manufacture of Ayurvedic, herbal, and dietary supplements under NIC divisions for pharmaceuticals, AYUSH products, and food preparations. (Source: Infomerics Report)

The nutraceuticals and Ayurvedic industry forms an important segment of the broader healthcare and wellness ecosystem, encompassing dietary supplements, functional foods, herbal formulations, and traditional medicinal products positioned across preventive, adjunct, and wellness-oriented care. The industry draws on a combination of modern nutritional science and established traditional medicine systems, particularly Ayurveda, to address long-term health maintenance, lifestyle-related conditions, and supportive therapy alongside conventional medical treatment. Demand for these products is closely linked to healthcare spending patterns, demographic shifts, and the growing emphasis on prevention and holistic well-being. As part of the regulated healthcare value chain, the industry is characterised by relatively high entry thresholds, driven by capital requirements, technical and formulation expertise, and a stringent regulatory environment, necessitating experience and compliance capabilities.

About Himalaya Nutravedics India

Himalaya Nutravedics India is engaged in the manufacturing, marketing and distribution of Ayurvedic and Nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and Nutraceutical companies. The company manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations, which are based on compositions and processes described in traditional Ayurvedic texts, proprietary Ayurvedic formulations and Nutraceutical products across multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, Liquid orals, Medicated oils. Over time, the company has expanded its presence as an Ayurvedic and Nutraceutical company, with a steadily increasing contribution from its own products.

Strengths of Himalaya Nutravedics India

• Integrated multi-dosage manufacturing capability.
  
• Doctor acceptance supported by product performance rather than mass advertising.
  
• Long-standing relationships with suppliers and customers.
  
• Geographic expansion achieved over a relatively short operating history.
  
• Broad therapeutic coverage across ayurvedic and nutraceutical segments.
  

Risks of Himalaya Nutravedics India

• They derive a significant portion of their revenue from the sale of products in the Ayurvedic products.
  
• They are dependent on and derive a substantial portion of their revenue from certain key customers.
  
• They have historically derived, and may continue to derive, a significant portion of their supply from top 10 suppliers.
  
• They operate out of a single manufacturing facility, located at Hyderabad, Telangana.
  
• The company is significantly dependent on the experience, expertise, and continued support of their promoters for the growth and development of their business.
  

The P/E Ratio has been computed based on the closing market price of equity shares on the BSE on May 11, 2026 divided by the Diluted EPS as on March 31, 2026, where EPS is adjusted for all the corporate actions up to May 11, 2026.

#As certified by J Singh & Associates with FRN: 110266W, Statutory Auditor of the Company, by way of their certificate dated May 15, 2026.

Jeena Sikho Lifecare Limited has not filed its financial result for financial year ended March 31, 2026 with the stock exchanges as of the date of this Draft Red Herring Prospectus, and accordingly, Revenue from Operations, EPS (Basic & Diluted), P/E, RoNW, Net Worth & NAV are based on financial year ended March 31, 2025. ^^To be updated upon finalization of the Price Band.

Anchor Investor Bidding Date

Monday, September 21, 2026

Book Running Lead Manager:
Nirbhay Capital Services Private Limited

Himalaya Nutravedics India Business Model

The company earns its revenue through the manufacturing, marketing and distribution of Ayurvedic and Nutraceutical formulations in India. They also undertake third-party contract manufacturing for other Ayurvedic and Nutraceutical companies.

Himalaya Nutravedics India Growth Trajectory

Himalaya Nutravedics India's Total Income for FY26 was ₹43.120 crores, whereas in FY25 and FY24 it was ₹20.997 crores and ₹14.429 crores, respectively.

The Profit After Tax for FY26 was ₹7.390 crores, whereas in FY25 and FY24 it was ₹2.232 crores and ₹0.426 crores, respectively.

Their EBITDA for FY26 was ₹8.103 crores, whereas in FY25 and FY24 it was ₹2.990 crores and ₹0.935 crores, respectively.

Himalaya Nutravedics India Market Position

Currently, the company has established a pan-India presence across multiple states, supported by a stockist-driven distribution network and an on-ground sales and marketing team comprising approximately 56 personnel, including regional managers and medical representatives.

As of March 31, 2026, the company’s products are marketed across multiple states in India, reflecting a well-diversified domestic footprint. Revenue contribution is relatively stronger from Telangana, Andhra Pradesh, Kerala, Gujarat, and Uttar Pradesh, driven by established distribution networks and higher penetration in these regions.

As of 31 March 2026, the company’s Total Income, Profit After Tax, and EBITDA were ₹43.120 crores, ₹7.390 crores, and ₹8.103 crores, respectively.

How to apply for Himalaya Nutravedics India IPO?

• Step 1: Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details. Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification. Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.